Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia

Haematologica. 2006 Aug;91(8):1145-6. Epub 2006 Jul 25.

Abstract

In 37 adults with chronic myeloid leukemia undergoing allogeneic stem cell transplantation imatinib prior to transplant had no discernible negative impact on 100-day mortality (13%) and severe acute (22%) or extensive chronic graft-versus- host disease (31%). After a median of 203 days (range: 18-1419) overall and progression-free survival rates are 62% and 54%, respectively.

Publication types

  • Letter

MeSH terms

  • Acute Disease
  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Chronic Disease
  • Combined Modality Therapy
  • Disease-Free Survival
  • Drug Administration Schedule
  • Graft vs Host Disease / epidemiology
  • Humans
  • Imatinib Mesylate
  • Incidence
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use*
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use*
  • Retrospective Studies
  • Stem Cell Transplantation / adverse effects
  • Stem Cell Transplantation / methods*
  • Stem Cell Transplantation / mortality
  • Time Factors
  • Transplantation, Homologous

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate